CHENGDU, China, July 27, 2022 – Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) today announced that it has entered into a research collaboration agreement with LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company discovering small molecule therapies that target aberrant DNA damage repair to treat Huntington’s disease and other triplet repeat diseases (TRDs). HitGen […]

Dr Ivarsson is currently Chief Development Officer at Moderna and led clinical trials of the company’s Covid-19 vaccine Cambridge, UK – 25th January 2022 – LoQus23 Therapeutics Ltd. (‘LoQus23’), a biotech discovering small molecule therapies that target aberrant DNA mismatch repair (MMR) to treat Huntington’s and other triplet repeat diseases, announces the appointment of Dr […]

Dr Caroline Benn (CSO ​of LoQus23) and Dr Ricardo Mouro Pinto (Massachusetts General Hospital) are co-recipients of a Friedreich’s Ataxia Research Alliance grant (supported by the Crisp Family Fund). Like Huntington’s disease, Friedreich’s ataxia ​(FA) is a trinucleotide repeat expansion disease that has somatic instability – but understanding of how this instability contributes to disease progression […]

We were delighted to be able to attend the Huntington’s Disease Society of America (HDSA) conference virtually. For our presentation, we thought it would be helpful for patients to understand why scientists and clinicians are so excited about the mismatch repair pathway in HD patients and what we are doing about it at LoQus23 Therapeutics. […]